Name: UMIN ID:
Unique ID issued by UMIN | UMIN000016439 |
---|---|
Receipt number | R000019091 |
Scientific Title | Phase II Clinical Study Evaluating the Efficacy and Safety of Cetuximab Rechallenge in Patients with Wild-Type RAS, Unresectable, Progressive/Recurrent Colorectal Cancer Refractory to Fluoropyrimidines, Oxaliplatin, Irinotecan, Cetuximab and Bevacizumab: The E-Rechallenge Trial |
Date of disclosure of the study information | 2015/02/04 |
Last modified on | 2024/01/16 16:23:50 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2015/02/04 14:56:42 | ||
2 | Update | 2015/04/20 15:13:17 | Organization Organization |
|
3 | Update | 2015/04/23 11:43:04 | Name of secondary funder(s) Name of secondary funder(s) |
|
4 | Update | 2016/03/08 16:45:31 | Last name of lead principal investigator Last name of lead principal investigator Organization Organization |
|
5 | Update | 2017/01/25 17:20:00 | Last follow-up date |
|
6 | Update | 2017/12/01 16:17:16 | Recruitment status Last follow-up date |
|
7 | Update | 2017/12/01 16:23:02 | Name of primary person or sponsor Organization Institutions |
|
8 | Update | 2019/11/22 13:43:49 | Recruitment status Date of IRB |
|
9 | Update | 2024/01/16 16:23:50 | Recruitment status |